Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 185

1.

Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring.

Gutiérrez F, Navarro A, Padilla S, Antón R, Masiá M, Borrás J, Martín-Hidalgo A.

Clin Infect Dis. 2005 Dec 1;41(11):1648-53. Epub 2005 Oct 19.

PMID:
16267739
2.

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T.

AIDS. 2001 Jan 5;15(1):71-5.

PMID:
11192870
3.

Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence.

Fumaz CR, Muñoz-Moreno JA, Moltó J, Negredo E, Ferrer MJ, Sirera G, Pérez-Alvarez N, Gómez G, Burger D, Clotet B.

J Acquir Immune Defic Syndr. 2005 Apr 15;38(5):560-5.

PMID:
15793366
4.
5.

Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.

Csajka C, Marzolini C, Fattinger K, Décosterd LA, Fellay J, Telenti A, Biollaz J, Buclin T.

Clin Pharmacol Ther. 2003 Jan;73(1):20-30.

PMID:
12545140
6.

Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study.

Manfredi R, Calza L, Chiodo F.

J Acquir Immune Defic Syndr. 2004 Apr 15;35(5):492-502.

PMID:
15021314
7.

Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis.

Weiner M, Benator D, Peloquin CA, Burman W, Vernon A, Engle M, Khan A, Zhao Z; Tuberculosis Trials Consortium.

Clin Infect Dis. 2005 Nov 1;41(9):1343-9. Epub 2005 Sep 29.

PMID:
16206114
8.

Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens.

Fumaz CR, Tuldrà A, Ferrer MJ, Paredes R, Bonjoch A, Jou T, Negredo E, Romeu J, Sirera G, Tural C, Clotet B.

J Acquir Immune Defic Syndr. 2002 Mar 1;29(3):244-53.

PMID:
11873073
9.

Are adverse events of nevirapine and efavirenz related to plasma concentrations?

Kappelhoff BS, van Leth F, Robinson PA, MacGregor TR, Baraldi E, Montella F, Uip DE, Thompson MA, Russell DB, Lange JM, Beijnen JH, Huitema AD; 2NN Study Group.

Antivir Ther. 2005;10(4):489-98.

PMID:
16038474
10.

Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals.

Clifford DB, Evans S, Yang Y, Acosta EP, Goodkin K, Tashima K, Simpson D, Dorfman D, Ribaudo H, Gulick RM.

Ann Intern Med. 2005 Nov 15;143(10):714-21.

PMID:
16287792
11.

Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen.

Lopez-Cortes LF, Ruiz-Valderas R, Ruiz-Morales J, Leon E, de Campos AV, Marin-Niebla A, Marquez-Solero M, Lozano F, Valiente R.

J Antimicrob Chemother. 2006 Nov;58(5):1017-23. Epub 2006 Sep 6.

PMID:
16956905
12.

Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.

McComsey G, Bhumbra N, Ma JF, Rathore M, Alvarez A; First Pediatric Switch Study.

Pediatrics. 2003 Mar;111(3):e275-81.

PMID:
12612284
13.
14.

Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin.

Manosuthi W, Sungkanuparph S, Thakkinstian A, Vibhagool A, Kiertiburanakul S, Rattanasiri S, Prasithsirikul W, Sankote J, Mahanontharit A, Ruxrungtham K.

AIDS. 2005 Sep 23;19(14):1481-6.

PMID:
16135901
15.

Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trial.

Read TR, Carey D, Mallon P, Mijch A, Goodall R, Hudson F, Wand H, Emery S.

AIDS. 2009 Oct 23;23(16):2222-3. doi: 10.1097/QAD.0b013e32832e95f8.

PMID:
19773634
16.

Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals.

Almond LM, Hoggard PG, Edirisinghe D, Khoo SH, Back DJ.

J Antimicrob Chemother. 2005 Oct;56(4):738-44. Epub 2005 Sep 1.

PMID:
16141277
17.

Efavirenz plasma levels for the prediction of treatment failure in heavily pretreated HIV-1 infected patients.

Langmann P, Weissbrich B, Desch S, Väth T, Schirmer D, Zilly M, Klinker H.

Eur J Med Res. 2002 Jul 24;7(7):309-14.

PMID:
12176680
19.

Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.

Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, Clifford DB, Hulgan T, Marzolini C, Acosta EP.

AIDS. 2004 Dec 3;18(18):2391-400.

PMID:
15622315
20.

Severe CNS side-effect and persistent high efavirenz plasma levels in a patient with HIV/HCV coinfection and liver cirrhosis.

Bickel M, Stephan C, Rottmann C, Carlebach A, Haberl A, Kurowski M, Staszewski S.

Scand J Infect Dis. 2005;37(6-7):520-2.

PMID:
16012018

Supplemental Content

Support Center